[RegenMD] Mesoblast Limited (ASX:MSB) Completes Acquisition Of Angioblast

RegenMD         Mesoblast Limited (ASX:MSB) Completes Acquisition Of Angioblast December 22, 2010 at 7:11 PM   Regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY) today announced that it had completed its acquisition of United States company ... See all stories on this topic »         Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement December 22, 2010 at 3:21 PM   The merged company will be entirely dedicated to the development of a regenerative medicine pipeline based on Pathfinder's novel cell therapy to address ... See all stories on this topic »         The NFL Charities Gives $1.6M to Various Sports-Related Research Projects December 22, 2010 at 1:54 PM   The fund granted researchers at Cornell University and Weill Cornell Medical College $100000 to research tissue engineering for spinal injuries, ... See all stories on this topic »         American CryoStem opens lab at Burlington County College incubator December 22, 2010 at 11:38 AM   The cells are then stored for future potential use in regenerative medicine or therapeutic, cellular-based medical procedures. ... See all stories on this topic »         UC system, BioTime in stem-cell deal December 22, 2010 at 11:38 AM   Alameda-based BioTime said the new agreement follows an earlier one reached with the California Institute for Regenerative Medicine -- the stem cell agency ... See all stories on this topic »         Regenicin to participate in San Francisco health conference OneMedForum in January December 22, 2010 at 11:38 AM   Regenerative medicine company Regenicin (OTCBB: RGIN) said Wednesday the company will participate in the fourth annual OneMedForum, to take place from ... See all stories on this topic » Proactive Investors USA & Canada         Research Assistant/Fellow in Biomedical Engineering December 22, 2010 at 10:06 AM   This exciting area of research offers benefits to a huge range of applications, from tissue engineering through to pharmaceutical development. ... See all stories on this topic » Nature.com         Regenicin CEO to Present at OneMedForum Business Development and Finance ... December 22, 2010 at 9:17 AM   Randall McCoy, CEO of Regenicin, will present the company's core concept and business model for bringing new regenerative medicine products to market. ... See all stories on this topic »         The extent of irreversible myocardial damage and the potential for left ventricular repair after primary percutaneous coronary intervention. December 22, 2010 at 8:13 AM   The extent of irreversible myocardial damage and the potential for left ventricular repair after primary percutaneous coronary intervention. Am Heart J. 2010 Dec;160(6 Suppl):S4-S10 Authors: Esposito G, Dellegrottaglie S, Chiariello M Primary percutaneous coronary intervention (PCI) is currently recognized as a highly effective therapy for acute myocardial infarction (AMI) and has been shown to decrease myocardial damage and improve prognosis. Several diagnostic tools have been proposed to evaluate the myocardium at risk, the occurrence of no-reflow, the final scar size, and the presence of residual viable myocardium in patients treated by primary PCI. A large body of literature documents the relevant impact of each of these variables on outcomes in patients treated for AMI. In patients undergoing primary PCI, a number of treatment approaches have been proposed recently to improve efficacy by increasing myocardial salvage. This article describes the principal diagnostic tools (ie, serum biochemical markers, electrocardiography, echocardiography, nuclear imaging techniques, magnetic resonance imaging, and multidetector computed tomography) applicable for evaluation of the size and severity of myocardial damage in patients with AMI undergoing primary PCI. Proposed therapeutic strategies to repair irreversible myocardial damage in patients treated with primary PCI are also considered, with particular focus on the value of stem cell therapy in this specific setting. PMID: 21147291 [PubMed - in process]         California Stem Cell Agency Expanding Staff, Looking for a Few New Hires December 22, 2010 at 5:09 AM         Biomaterials: Close to the bone December 22, 2010 at 4:02 AM   Tissue engineering, which uses stem cells, growth factors and scaffolds—porous structures for supporting cell proliferation, differentiation and tissue ... See all stories on this topic » Nanowerk LLC         Marshall Research Institute Adds Expert In Bone Growth And Development December 22, 2010 at 3:07 AM   Xie has more than 10 years experience in biomaterials, tissue engineering, micro-/nanofabrication, biosurfaces, formulations, drug delivery, ... See all stories on this topic »             This email was sent to agupta1213+termsc@gmail.com. Delivered by Feed My Inbox PO Box 682532 Franklin, TN 37068 Account Login Unsubscribe Here